7910 Woodmont Avenue,Suite 1210
Bethesda, Maryland 20814, U.S.A. 
info@mlsvfund.com |   +1 301 298 5455

© 2018  by MASA Life Science Ventures, LP

NEWS

September 19, 2019

​CRESTWOOD, Ky. and WALTHAM, Mass., - Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, t...

September 4, 2019

​CRESTWOOD, Ky. and WALTHAM, Mass., - Apellis Pharmaceuticals Inc., (Nasdaq:APLS) announced today the dosing of the first patient in the Phase 3 clinical study PRINCE (APL2-308), evaluating the efficacy and safety of APL-2 for treatment-naïve patient...

July 23, 2019

​CRESTWOOD, Ky. and WALTHAM, Mass., - Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, a...

July 19, 2019

​CRESTWOOD, Ky. and WALTHAM, Mass., - Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the control of the complement system, toda...

June 28, 2019

​CRESTWOOD, Ky. and WALTHAM, Mass., - Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, t...

March 12, 2019

​CRESTWOOD, Ky. and WALTHAM, Mass., - Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, t...

March 5, 2019

No inflammation observed in ten patients dosed in Phase 1b trial with new intravitreal APL-2 drug product from modified manufacturing process

​CRESTWOOD, Ky. and WALTHAM, Mass., - Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmac...

February 28, 2019

Apellis to receive up to $120 million in upfront and near-term milestone payments, with the potential for additional payments subject to mutual agreement

Apellis retains exclusive worldwide commercial rights to APL-2 in all indications

​CRESTWOOD, Ky....

February 12, 2019

New designation now includes all PNH patients

​CRESTWOOD, Ky. and WALTHAM, Mass., - Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat diseases thro...

December 21, 2018

​CRESTWOOD, Ky. and WALTHAM, Mass., - Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat diseases through inhibition of the complement system, toda...

Please reload

Featured Posts
Please reload

See News By Company
See News By Month
Please reload